Intervet/Schering-Plough opens new vaccine manufacturing facility

Boxmeer, Netherlands

-- Intervet/Schering-Plough Animal Health opened its new $22 million vaccine production facility today in Boxmeer, Netherlands.

The new facility has increased the floor space of the bacterial vaccine production unit from 1,500 square meters to more than 5,500 square meters and includes four high-tech production lines for bacterial vaccines, the company says.

Intervet/Schering-Plough Animal Health will celebrate the opening with a dedicated scientific symposium titled “Research and Technology in Bacterial Vaccine Development: Opportunities for a One Health Approach.” Several experts from Dutch universities and research institutions will present on developments in bacterial vaccine research and development.

“The new bacteriological processing unit here in Boxmeer illustrates the ongoing investments in innovation that this company is making,” says Malte Greune, senior vice president of animal health manufacturing for Intervet/Schering-Plough Animal Health. “We believe that this facility and its equipment, as well as the people who work here, all contribute to the success of our business. Moreover, it is yet another example of our integrated technology strategy, where we combine our expertise along the production process from making small amounts of vaccine in a laboratory, via upscaling in our pilot production plant, and finally to commercial large-scale batch manufacturing.”